Literature DB >> 20537411

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies.

Anne Waschbisch1, Nicholas Schwab, Tobias Ruck, Max-Philipp Stenner, Heinz Wiendl.   

Abstract

FOXP3+ T regulatory cells (Tregs) are considered key players in the maintenance of immune homeostasis. Here we studied the presence and potential role of FOXP3+ Tregs in myositis. CD3 and FOXP3 expression in dermatomyositis, polymyositis and inclusion body myositis was assessed by immunohistochemistry and real-time PCR. FOXP3+ Tregs were found in close proximity to effector cells and their numbers correlated with the degree of inflammation. Despite divergent pathogenetic concepts, we observed no differences in the frequency of FOXP3 immunoreactive cells or FOXP3 mRNA expression between different myositis entities. Functional assays using human myoblasts as targets of CD8+ cells demonstrate that Tregs are capable to inhibit the lytic activity of cytotoxic cells. Our data suggest that FOXP3 Tregs serve to counterbalance muscle destruction by cytotoxic T cells in myositis. Copyright 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20537411     DOI: 10.1016/j.jneuroim.2010.03.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

1.  Diagnosis and treatment of inflammatory myopathy: issues and management.

Authors:  Christine Castro; Mark Gourley
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

2.  Chronic infection stunts macrophage heterogeneity and disrupts immune-mediated myogenesis.

Authors:  Richard M Jin; Jordan Warunek; Elizabeth A Wohlfert
Journal:  JCI Insight       Date:  2018-09-20

Review 3.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

4.  Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets.

Authors:  F Espinosa-Ortega; D Gómez-Martin; K Santana-De Anda; J Romo-Tena; P Villaseñor-Ovies; J Alcocer-Varela
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

5.  Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.

Authors:  Ruxue Yin; Gangjian Wang; Lei Zhang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

6.  Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Authors:  Karsten Schmidt; Konstanze Kleinschnitz; Goran Rakocevic; Marinos C Dalakas; Jens Schmidt
Journal:  BMC Neurol       Date:  2016-04-16       Impact factor: 2.474

Review 7.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 8.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 9.  Pathogenesis, classification and treatment of inflammatory myopathies.

Authors:  Mei Zong; Ingrid E Lundberg
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

Review 10.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.